significant rise in the us overnight, page-4

plenty of upside coming for this company.
http://www.psivida.com/News/download/Presentations/Rodman%20&%20Renshaw%20May%202008.pdf



Company Highlights

Proven drug delivery business model

�� Complementary and broadly-applicable technologies
• Well positioned in Ophthalmology
• Potential to expand into other fields

�� FDA Approved Products on the Market
• Retisert is the only FDA approved product for posterior uveitis
• Vitrasert approved in US, EU, and Japan for CMV retinitis

�� Broad and well-balanced R&D pipeline
• Medidur for diabetic macular edema (DME) – Phase III pivotal trials
• BrachySil for pancreatic cancer – Entering Phase IIb trials
• Significant collaboration agreement with Pfizer

�� Upside for Shareholders

�� Significant revenue potential from fully funded ophthalmic programs with different
partners (in DME, age related macular degeneration and others)

�� Possible additional partnerships from BioSilicon technology, (furthest advanced
application in Phase II trials)

�� Anticipate reincorporation as US-based, NASDAQ-listed company